The "Wegovy" brand slimming syringe is sold in the Achat pharmacy in Mitte. The "Wegovy" slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox.
Subscribe here to receive future editions. Happy Thursday! New research showing additional health benefits of the weight loss drug Wegovy seems to crop up every week. This time around, Novo Nordisk 's blockbuster treatment helped reduce knee pain in patients with a type of arthritis and obesity, according to research published Wednesday in the New England Journal of Medicine.
The study was funded by Novo Nordisk, which is conducting several studies on the other potential treatment uses of semaglutide, the active ingredient in Wegovy. The results of the 68-week trial could be a big deal for the Danish drugmaker: It could pave the way for regulatory approval of semaglutide for osteoarthritis, a degenerative joint disease that causes the cartilage and bone in your joints to break down over time. It would be yet another expansion of the accepted uses for the blockbuster drug.
It's the most common type of arthritis and affects around 33 million people in the U.S., according to the Centers for Disease Control and Prevention.
The condition is not a regular part of aging, but it is common among adults 45 and above. So, how is the condition related to .
